Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients

OBJECTIVE: To examine humoral and cellular response in multiple sclerosis patients on anti-CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination. METHODS: A prospective longitudinal study design from first throughout third vaccination in Danish and American MS centers. All participants were...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajwa, Hamza Mahmood, Novak, Frederik, Nilsson, Anna Christine, Nielsen, Christian, Holm, Dorte K., Østergaard, Kamilla, Witt, Agnes Hauschultz, Byg, Keld-Erik, Johansen, Isik S., Mittl, Kristen, Rowles, William, Zamvil, Scott S., Bove, Riley, Sabatino, Joseph J., Sejbaek, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898195/
https://www.ncbi.nlm.nih.gov/pubmed/35334278
http://dx.doi.org/10.1016/j.msard.2022.103729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898195/
https://www.ncbi.nlm.nih.gov/pubmed/35334278
http://dx.doi.org/10.1016/j.msard.2022.103729

Ejemplares similares